vortioxetine

The most common side effects reported with vortioxetine are nausea, vomiting, diarrhea, headache, and dizziness.

In an article published in February 2013, Lundbeck scientists report that vortioxetine enhances some forms of memory in rats.

Brintellix (vortioxetine) - a novel antidepressant with multimodal activity described as "serotonin modulator and stimulator".

While the first demonstrated vortioxetine's superiority over the placebo, the second showed that the drug had no efficacy, leading the authors to question the designs of the different trials.

In August 2012, a randomized, double-blind trial confirms the superiority of vortioxetine over placebo according to all measures, excepted the Sheehan Disability scale.

In May 2011, Lundbeck presented the results of four phase III trials on vortioxetine at the 2011 Annual Meeting of the American Psychiatric Association.

In May 2012, Lundbeck disclosed the results of three phase III clinical trials, showing vortioxetine's superiority over placebo according to the MADRS.

Similarly, in May 2012, Lundbeck published the results of a double-blind, randomized, placebo-controlled clinical trial with duloxetine evaluating vortioxetine in elderly depressed patients, and it was found superior to placebo, with fewer side effects than duloxetine.

Concerns have been raised as to why Lundbeck are trialing vortioxetine alongside drugs such as venlafaxine (well known for its side effects) and not other drugs like escitalopram (which has a lower side effect profile and which Lundbeck promotes as its most effective treatment for depressive disorders).